drugset / Trial / NCT00268385

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

NCT00268385

Phase 1 Active not recruiting 83 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating patients with malignant gliomas. Drugs used in chemotherapy, such as vorinostat and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may help temozolomide work better by making tumor cells more sensitive to the drug. Giving vorinostat together with temozolomide may kill more tumor cells.

Timeline

Start
2005-12-16
Primary completion
2018-10-18
Completion
2027-04-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Temozolomide Small molecule Oral
Subject Vorinostat Small molecule Oral